Blake Williamson, MD, MPH, invites Steven Dell, MD, to discuss the recent release of a new presbyopia drop—VIZZ (aceclidine ophthalmic solution, 1.44%; Lenz Therapeutics). Dr. Dell outlines why this drop represents a game-changing option for presbyopia therapy. The once-daily drop lasts for 10 hours and results in a sub-2-mm pupil size to achieve significant gains in near vision. They also review the innovation cycle of this product and how patients have responded to the treatment so far.